Literature DB >> 25043405

Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition.

Valerie Sapp1, Leah Gaffney, Steven F EauClaire, Randolph P Matthews.   

Abstract

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD), the accumulation of lipid within hepatocytes, is increasing in prevalence. Increasing fructose consumption correlates with this increased prevalence, and rodent studies directly support fructose leading to NAFLD. The mechanisms of NAFLD and in particular fructose-induced lipid accumulation remain unclear, although there is evidence for a role for endoplasmic reticulum (ER) stress and oxidative stress. We have evidence that NAFLD models demonstrate activation of the target of rapamycin complex 1 (Torc1) pathway. We set out to assess the contribution of ER stress, oxidative stress, and Torc1 up-regulation in the development of steatohepatitis in fructose-treated larval zebrafish. Zebrafish were treated with fructose or glucose as a calorie-matched control. We also treated larvae with rapamycin, tunicamycin (ER stress), or valinomycin (oxidative stress). Fish were stained with oil red O to assess hepatic lipid accumulation, and we also performed quantitative polymerase chain reaction (qPCR)and western blot analysis. We performed immunostaining on samples from patients with NAFLD and nonalcoholic steatohepatitis (NASH). Treatment with fructose induced hepatic lipid accumulation, mitochondrial abnormalities, and ER defects. In addition, fructose-treated fish showed activation of inflammatory and lipogenic genes. Treatment with tunicamycin or valinomycin also induced hepatic lipid accumulation. Expression microarray studies of zebrafish NAFLD models showed an elevation of genes downstream of Torc1 signaling. Rapamycin treatment of fructose-treated fish prevented development of hepatic steatosis, as did treatment of tunicamycin- or valinomycin-treated fish. Examination of liver samples from patients with hepatic steatosis demonstrated activation of Torc1 signaling.
CONCLUSION: Fructose treatment of larval zebrafish induces hepatic lipid accumulation, inflammation, and oxidative stress. Our results indicate that Torc1 activation is required for hepatic lipid accumulation across models of NAFLD, and in patients.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25043405     DOI: 10.1002/hep.27284

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

Review 1.  Zebrafish: an important tool for liver disease research.

Authors:  Wolfram Goessling; Kirsten C Sadler
Journal:  Gastroenterology       Date:  2015-08-28       Impact factor: 22.682

Review 2.  Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction.

Authors:  Metin Basaranoglu; Gokcen Basaranoglu; Elisabetta Bugianesi
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

3.  Fructose and glucose can regulate mammalian target of rapamycin complex 1 and lipogenic gene expression via distinct pathways.

Authors:  Yue Hu; Ivana Semova; Xiaowei Sun; Hong Kang; Satyapal Chahar; Anthony N Hollenberg; David Masson; Matthew D Hirschey; Ji Miao; Sudha B Biddinger
Journal:  J Biol Chem       Date:  2017-12-08       Impact factor: 5.157

4.  Palmitic Acid-Enriched Diet Induces Hepatic Steatosis and Injury in Adult Zebrafish.

Authors:  Ki-Hoon Park; Zhi-Wei Ye; Jie Zhang; Seok-Hyung Kim
Journal:  Zebrafish       Date:  2019-07-29       Impact factor: 1.985

5.  Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH.

Authors:  Melanie Tran; Sang-Min Lee; Dong-Ju Shin; Li Wang
Journal:  JCI Insight       Date:  2017-11-02

Review 6.  LITTLE FISH, BIG DATA: ZEBRAFISH AS A MODEL FOR CARDIOVASCULAR AND METABOLIC DISEASE.

Authors:  Philipp Gut; Sven Reischauer; Didier Y R Stainier; Rima Arnaout
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

Review 7.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

8.  Rapamycin attenuates liver injury caused by vinyl chloride metabolite chloroethanol and lipopolysaccharide in mice.

Authors:  Anna L Lang; Austin M Krueger; Regina D Schnegelberger; Brenna R Kaelin; Maxwell J Rakutt; Liya Chen; Gavin E Arteel; Juliane I Beier
Journal:  Toxicol Appl Pharmacol       Date:  2019-09-06       Impact factor: 4.219

Review 9.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

10.  Higher plain water intake is related to lower newly diagnosed nonalcoholic fatty liver disease risk: a population-based study.

Authors:  Xing Wang; Shiyu Lin; Shinan Gan; Yeqing Gu; Ying Yang; Qing Zhang; Li Liu; Ge Meng; Zhanxin Yao; Dong Zheng; Hongmei Wu; Shunming Zhang; Yawen Wang; Tingjing Zhang; Shaomei Sun; Qiyu Jia; Kun Song; Xiao-Hui Wu; Yuntang Wu; Kaijun Niu
Journal:  Eur J Clin Nutr       Date:  2021-04-09       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.